Genetic Tests: Clinical Validity and Clinical Utility

Wylie Burke1

1 University of Washington, Seattle, Washington
Publication Name:  Current Protocols in Human Genetics
Unit Number:  Unit 9.15
DOI:  10.1002/0471142905.hg0915s81
Online Posting Date:  April, 2014
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

When evaluating the appropriate use of new genetic tests, clinicians and health care policymakers must consider the accuracy with which a test identifies a patient's clinical status (clinical validity) and the risks and benefits resulting from test use (clinical utility). Genetic tests in current use vary in accuracy and potential to improve health outcomes, and these test properties may be influenced by testing technology and the clinical setting in which the test is used. This unit defines clinical validity and clinical utility, provides examples, and considers the implications of these test properties for clinical practice. Curr. Protoc. Hum. Genet. 81:9.15.1‐9.15.8. © 2014 by John Wiley & Sons, Inc.

Keywords: clinical validity; clinical utility; predictive value; penetrance

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Introduction
  • Clinical Validity
  • Clinical Utility
  • Literature Cited
  • Figures
  • Tables
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

  Abboud, R.T., Ford, G.T., and Chapman, K.R. Standards Committee of the Canadian Thoracic Society. 2001. α1‐antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can. Respir. J. 8:81‐88.
  Allen, K.J., Gurrin, L.C., Constantine, C.C., Osborne, N.J., Delatycki, M.B., Nicoll, A.J., McLaren, C.E., Bahlo, M., Nisselle, A.E., Vulpe, C.D., Anderson, G.J., Southey, M.C., Giles, G.G., English, D.R., Hopper, J.L., Olynyk, J.K., Powell, L.W., and Gertig, D.M. 2008. Iron‐overload‐related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358:221‐230.
  Altshuler, D. and Daly, M. 2007. Guilt beyond a reasonable doubt. Nat. Genet. 39:813‐815.
  Asberg, A., Hveem, K., Kannelønning, K., and Irgens, W.Ø. 2007. Penetrance of the C28Y/C282Y genotype of the HFE gene. Scand. J. Gastroenterol. 42:1073‐1077.
  Ashley‐Koch, A., Yang, Q., and Olney, R.S. 2000. Sickle hemoglobin (Hb S) allele and sickle cell disease. Am. J. Epidemiol. 151:839‐845.
  Begg, C.B. 2002. On the use of familial aggregation in population‐based case probands for calculating penetrance. J. Natl. Cancer Inst. 94:1221‐1226.
  Beutler, E. 2007. Iron storage disease: Facts, fiction and progress. Blood Cells Mol. Dis. 39:140‐147.
  Brandi, M.L., Gagel, R.F., Angeli, A., Bilezekian, J.P., Beck‐Peccoz, P., Bordi, C., Conte‐Devolx, B., Falchetti, A., Gheri, R.G., Libroia, A., Lips, C.J., Lombardi, C., Mannelli, M., Pacini, F., Pnder, B.A., Raue, F., Skogseid, B., Tamburrano, G., Thakker, R.V., Thompson, N.W., Tomassetti, P., Tonelli, F., Wells, S.A. Jr., and Mar, S.J. 2001. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86:5658‐5671.
  Burke, W. and Austin, M.A. 2002. Genetic risk in context: Calculating the penetrance of BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 94:1185‐1187.
  Burke, W. and Psaty, B.M. 2007. Personalized medicine in the era of genomics. JAMA 298:1682‐1684.
  Burke, W., Atkins, D., Gwinn, M., Guttmacher, A., Haddow, J., Lau, J., Palomaki, G., Press, N., Richards, C.S., Wideroff, L., and Wiesner, G.L. 2002. Genetic test evaluation: Information needs of clinicians, policy‐makers and the public. Am. J. Epidemiol. 156:311‐318.
  Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A., and Goldgar, D.E. 1994. Risks of cancer in BRCA1‐mutation carriers: Breast Cancer Linkage Consortium. Lancet 343:692‐695.
  Gan, E.K., Powell, L.W., and Olynyk, J.K. 2011. Natural history and management of HFE‐hemochromatosis. Semin. Liver Dis. 31:293‐301.
  Grody, W.W., Thompson, B.H., Gregg, A.R., Bean, L.H., Monaghan, K.G., Schneider, A., and Lebo, R.V. 2013. ACMG position statement on prenatal/preconception expanded carrier screening. Genet. Med. 15:482‐483.
  Hansen, E., Imperatore, P., and Burke, W. 2001. HFE gene and hemochromatosis: A HuGE review. Am. J. Epidemiol. 154:193‐206.
  Holtzman, N.A. and Watson, M.S. 1999. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. Johns Hopkins University Press, Baltimore, Maryland.
  Humphries, S., Ridker, P.M., and Talmud, P.J. 2004. Genetic testing for cardiovascular disease susceptibility: A useful clinical management tool or possible misinformation. Arteroscler. Thromb. Vasc. Biol. 24:1‐9.
  Janssens, A.C., Ioannidis, J.P., van Duijn, C.M., Little, J., Khoury, M.J.; GRIPS Group. 2011. Strengthening the reporting of Genetic Risk Prediction Studies: The GRIPS statement. Genet Med. 13:453‐456.
  Jarvinen, H.J., Aarnio, M., Mustonene, H., Aktan‐Collan, K., Aaltonen, L.A., Peltomaki, P., De La Chapelle, A., and Mecklin, J.P. 2000. Controlled 15‐year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829‐834.
  Khoury, M.J., Janssens, A.C., and Ransohoff, D.F. 2013. How can polygenic inheritance be used in population screening for common diseases? Genet Med. 15:437‐443.
  Lebo, R.V. and Grody, W.W. 2007. Testing and reporting ACMG cystic fibrosis mutation panel results. Genet. Test. 11:11‐31.
  Levy‐Lahad, E. and Friedman, E. 2007. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 96:11‐15.
  Nebert, D.W., Zhang, G., and Vesell, E.S. 2008. From human genetics and genomics to pharmacogenetics and pharmacogenomics: Past lessons, future directions. Drug Metab. Rev. 40:187‐224.
  Raue, F. and Frank‐Raue, K. 2010. Update multiple endocrine neoplasia type 2. Fam. Cancer 9:449‐457.
  Shuen, A.Y. and Foulkes, W.D. 2011. Inherited mutations in breast cancer genes–risk and response. J. Mammary Gland Biol. Neoplasia 16:3‐15.
  Simonds, N.I., Khoury, M.J., Schully, S.D., Armstrong, K., Cohn, W.F., Fenstermacher, D.A., Ginsburg, G.S., Goddard, K.A., Knaus, W.A., Lyman, G.H., Ramsey, S.D., Xu, J., and Freedman, A.N. 2013. Comparative effectiveness research in cancer genomics and precision medicine: Current landscape and future prospects. J. Natl. Cancer Inst. 105:929‐936.
  Sivakumaran, S., Agakov, F., Theodoratou, E., Prendergast, J.G., Zgaga, L., Manolio, T., Rudan, I., McKeigue, P., Wilson, J.F., and Campbell, H. 2011. Abundant pleiotropy in human complex diseases and traits. Am. J. Hum. Genet. 89:607‐618.
  Skinner, M.A., Moley, J.A., Dilley, W.G., Owzar, K., Debenedetti, M.K., and Wells, S.A. Jr. 2005. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med. 353:1105‐1113.
  U.S. Preventive Services Task Force. 2006. Screening for hemochromatosis: Recommendation statement. Ann. Intern. Med. 145:204‐208.
  Vasen, H.F., Blanco, I., Aktan‐Collan, K., Gopie, J.P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., Colas, C., Engel, C., Frayling, I.M., Genuardi, M., Heinimann, K., Hes, F.J., Hodgson, S.V., Karagiannis, J.A., Lalloo, F., Lindblom, A., Mecklin, J.P., Møller, P., Myrhoj, T., Nagengast, F.M., Parc, Y., Ponz de Leon, M., Renkonen‐Sinisalo, L., Sampson, J.R., Stormorken, A., Sijmons, R.H., Tejpar, S., Thomas, H.J., Rahner, N., Wijnen, J.T., Järvinen, H.J., Möslein, G.; Mallorca group. 2013. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts. Gut 62:812‐823.
  Wilken, B. 2001. Rare disease and the assessment of intervention: What sorts of clinical trials can we use? J. Inherit Metab. Dis. 24:291‐298.
  Woolf, S.H. 2000. Evidence‐based medicine and practice guidelines: An overview. Cancer Control 7:362‐367.
  World Health Organization. 1997. α1‐Antitypsin deficiency: Memorandum from a WHO meeting. Bull. World Health Org. 75:397‐415.
  Zamora, N.P., Pla, R.V., Del Rio, P.G., Margaleff, R.J., Frias, F.R., and Ronsano, J.B. 2008. Intravenous human plasma‐derived augmentation therapy in alpha 1‐antitrypsin deficiency: From pharmacokinetic analysis to individualizing therapy. Ann. Pharmacother. 42:640‐646.
Internet Resources
  http://www.cms.hhs.gov/clia/
  Clinical Laboratory Improvement Amendments (CLIA) Home Page.
  http://www.genetests.org
  GeneTests Web site with link to online journal GeneReviews, containing the following articles: Shohat, M. and Halpern, G.J. 2012. Familial Mediterranean fever; and Moline and Eng C. 2013. Multiple endocrine neoplasia type 2.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library